UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2–positive subgroup-Reference-Cited by-同舟云学术

UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2–positive subgroup

Published:2019-11 Issue: Volume:122 Page:91-100
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

D'Hondt Véronique,Canon Jean-Luc,Roca Lise,Levy Christelle,Pierga Jean-Yves,Le Du Fanny,Campone Mario,Desmoulins Isabelle,Goncalves Anthony,Debled Marc,Rios Maria,Ferrero Jean-Marc,Serin Daniel,Hardy-Bessard Anne-Claire,Piot Gilles,Brain Etienne^ORCID,Dohollou Nadine,Orfeuvre Hubert,Lemonnier Jerome^ORCID,Roché Henri,Delaloge Suzette^ORCID,Dalenc Florence^ORCID

Funder

Roche

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference22 articles.

1. Polychemotherapy for early breast cancer: an overview of the randomised trials;The Lancet,1998

2. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials;Early Breast Cancer Trialists’ Collaborative Group (EBCTCG);The Lancet,2012

3. Trastuzumab for patients with axillary-node–positive breast cancer: results of the FNCLCC-PACS 04 trial;Spielmann;J Clin Oncol,2009

4. Reporting results of cancer treatment;Miller;Cancer,1981

5. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial;Mackey;Lancet Oncol,2013

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-07

2. Changing the role of pCR in breast cancer treatment - an unjustifiable interpretation of a good prognostic factor as a “factor for a good prognosis“;Frontiers in Oncology;2023-07-18

3. Protocol for pyrotinib cardiac safety in patients with HER2-positive early or locally advanced breast cancer–The EARLY-MYO-BC study;Frontiers in Cardiovascular Medicine;2023-02-10

4. Efficacy analysis of neoadjuvant chemotherapy with or without anthracyclines in female patients with HER2-positive breast cancer in China: a nationwide, multicenter, 10-year retrospective study (CSBrS-012);Therapeutic Advances in Medical Oncology;2023-01

5. Crossover in Adjuvant Trastuzumab Trials;American Journal of Clinical Oncology;2022-09-08